Nuvectis Pharma (NVCT) Corporate presentation summary

Corporate overview and funding

• Completed a $115M follow-on offering in July 2026; presentation cites multiple near-term clinical and regulatory catalysts.

• Entered a licensing agreement with Haisco in June 2026; Haisco has ~50 marketed products, ~70 research programs and licensing deals with Eli Lilly and AbbVie.

• Management includes Ron Bentsur, CEO and president; Enrique Poradosu, chief scientific and business officer; and Shay Shemesh, chief development and operations officer.

Ciprocopan (NXP100)

• Oral, once-daily Factor B inhibitor; approved in China for treatment-naïve PNH, with approval for previously treated PNH pending.

• In treatment-naïve PNH, 59.5% achieved Hgb >12 g/dL with ciprocopan vs 8.3% with eculizumab; average Hgb increases were 5.0 vs 2.2 g/dL.

• Previously treated PNH study met its primary endpoint, with a 52.8% response rate for Hgb ≥12 g/dL; the lower bound of the 95% CI exceeded the prespecified 20% threshold.

• Phase 2 IgAN data showed UPCR reductions of 33% at week 4, 45.3% at week 12 and 57.7% at week 24; eGFR change at week 24 was +2.74 vs -1.97 for placebo.

• Pivotal Phase 3 IgAN and Phase 2 lupus nephritis studies are ongoing in China; additional development opportunities include MG, dry AMD and C3G.

NXP200

• Oral, brain-penetrant, paradox-breaker BRAF inhibitor; Phase 1b expansion in China is ongoing in BRAF-mutated solid tumors, with Breakthrough Therapy Designation in China for recurrent or progressive BRAF V600-mutant high-grade glioma.

• In the free-base Phase 1 dose-escalation study, NXP200 produced a 37% ORR (7/19), including one CR, in high-grade glioma; no DLTs or drug-related discontinuations or deaths were reported.

• ESMO 2026 update reported HGG ORR of 40.0% and DCR of 85.0% (N=20); LGG ORR was 42.9% and DCR 85.7% (N=7).

• In a human bridging study, the new salt form showed greater than 6x exposure; preliminary single-agent data included confirmed partial responses in colorectal cancer and papillary thyroid carcinoma.